Routine UK Funding OKd For Tagrisso In First & Second-Line NSCLC
Executive Summary
Health technology assessment body NICE has published two final guidance documents that cover the use of AstraZeneca’s drug at different points in the treatment pathway for locally advanced or metastatic EGFR-positive non-small cell lung cancer.